88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting
Authors: ROSENSTOCK JULIO , ALI AMAR , MEIER JURIS J. , GIORGINO FRANCESCO , GUJA CRISTIAN , PRAZNY MARTIN , LUBWAMA ROBERT , SOUHAMI ELISABETH , BLONDE LAWRENCE 
Published: June 2020

iGlarLixi, the once-daily fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide, has been shown to robustly improve glycemic control in adults with T2D.

To assess the effects of iGlarLixi with SGLT2i in T2D, we conducted subgroup analyses according to SGLT2i use in the following populations: 1) adults uncontrolled on GLP-1 receptor agonists (GLP-1 RAs) and oral antidiabetic drugs (OADs) switching to iGlarLixi in the 26-week LixiLan-G RCT (NCT02787551) and 2) adults switching to or adding iGlarLixi in a 6-month, retrospective real-world observational study using data from the U.S. Optum-Humedica electronic medical records database. Endpoints included change in HbA1c and hypoglycemia incidence and event rates.

Across the studies, there were no major differences in baseline characteristics for those who initiated iGlarLixi while already using SGLT2i (N=346) and those initiating iGlarLixi without background SGLT2i use (N=1285). HbA1c reductions from baseline to week 26 and hypoglycemia incidence and event rates were similar for iGlarLixi regardless of SGLT2i use (Table).

In conclusion, evidence from both RCT and real-world clinical settings support the efficacy and safety of iGlarLixi when used in combination with SGLT2i.

Disclosure

J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb, Genentech, Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pfizer Inc., REMD Biotherapeutics. Other Relationship; Self; Applied Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. A. Ali: Advisory Panel; Self; Eli Lilly and Company, Napp Pharmaceuticals, Novo Nordisk A/S, Sanofi. Research Support; Self; Eli Lilly and Company, Gelesis. Speaker’s Bureau; Self; Eli Lilly and Company, Novo Nordisk A/S, Sanofi. Stock/Shareholder; Self; Amarin Corporation. J.J. Meier: Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi. F. Giorgino: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk Inc., Roche Diabetes Care, Sanofi. Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., LifeScan, Inc., MedImmune, Merck Sharp & Dohme Corp., Roche Diabetes Care, Sanofi. Research Support; Self; Eli Lilly and Company, LifeScan, Inc., Takeda Development Centre Europe Ltd. C. Guja: Advisory Panel; Self; AstraZeneca, Sanofi. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Servier. M. Prazny: Speaker’s Bureau; Self; Novartis Pharmaceuticals Corporation, Roche Diabetes Care. Other Relationship; Self; Abbott, Boehringer Ingelheim International GmbH, Lilly Diabetes, Medtronic, Novo Nordisk A/S, Sanofi, Teva Pharmaceutical Industries Ltd. R. Lubwama: Employee; Self; Sanofi US. E. Souhami: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. L. Blonde: Advisory Panel; Self; AstraZeneca, Gilead Sciences, Inc. Consultant; Self; Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; Janssen Scientific Affairs, LLC., Novo Nordisk A/S, Sanofi. Speaker’s Bureau; Self; Janssen Pharmaceuticals, Inc., Sanofi.

Funding

Sanofi